Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab.
Identifieur interne : 003C02 ( Main/Exploration ); précédent : 003C01; suivant : 003C03Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab.
Auteurs : Erik Stroes [Pays-Bas] ; David Colquhoun [Australie] ; David Sullivan [Australie] ; Fernando Civeira [Espagne] ; Robert S. Rosenson [États-Unis] ; Gerald F. Watts [Australie] ; Eric Bruckert [France] ; Leslie Cho [États-Unis] ; Ricardo Dent [États-Unis] ; Beat Knusel [États-Unis] ; Allen Xue [États-Unis] ; Rob Scott [États-Unis] ; Scott M. Wasserman [États-Unis] ; Michael Rocco [États-Unis]Source :
- Journal of the American College of Cardiology [ 1558-3597 ] ; 2014.
Descripteurs français
- KwdFr :
- Adolescent, Adulte, Anticorps monoclonaux (), Anticorps monoclonaux (administration et posologie), Anticorps monoclonaux (immunologie), Anticorps monoclonaux (sang), Apoptose, Association de médicaments, Calendrier d'administration des médicaments, Cholestérol (sang), Femelle, Humains, Hypercholestérolémie (immunologie), Hypercholestérolémie (sang), Hypercholestérolémie (traitement médicamenteux), Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase (administration et posologie), Jeune adulte, Mâle, Méthode en double aveugle, Proprotein convertases (antagonistes et inhibiteurs), Proprotein convertases (immunologie), Proprotéine convertase 9, Résultat thérapeutique, Serine endopeptidases (immunologie), Sujet âgé, Tolérance aux médicaments, Études de suivi.
- MESH :
- administration et posologie : Anticorps monoclonaux, Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase.
- antagonistes et inhibiteurs : Proprotein convertases.
- immunologie : Anticorps monoclonaux, Hypercholestérolémie, Proprotein convertases, Serine endopeptidases.
- sang : Anticorps monoclonaux, Cholestérol, Hypercholestérolémie.
- traitement médicamenteux : Hypercholestérolémie.
- Adolescent, Adulte, Anticorps monoclonaux, Apoptose, Association de médicaments, Calendrier d'administration des médicaments, Femelle, Humains, Jeune adulte, Mâle, Méthode en double aveugle, Proprotéine convertase 9, Résultat thérapeutique, Sujet âgé, Tolérance aux médicaments, Études de suivi.
English descriptors
- KwdEn :
- Adolescent, Adult, Aged, Antibodies, Monoclonal (administration & dosage), Antibodies, Monoclonal (blood), Antibodies, Monoclonal (drug effects), Antibodies, Monoclonal (immunology), Apoptosis, Cholesterol (blood), Double-Blind Method, Drug Administration Schedule, Drug Therapy, Combination, Drug Tolerance, Female, Follow-Up Studies, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors (administration & dosage), Hypercholesterolemia (blood), Hypercholesterolemia (drug therapy), Hypercholesterolemia (immunology), Male, Proprotein Convertase 9, Proprotein Convertases (antagonists & inhibitors), Proprotein Convertases (immunology), Serine Endopeptidases (immunology), Treatment Outcome, Young Adult.
- MESH :
- chemical , administration & dosage : Antibodies, Monoclonal, Hydroxymethylglutaryl-CoA Reductase Inhibitors.
- chemical , antagonists & inhibitors : Proprotein Convertases.
- chemical , blood : Antibodies, Monoclonal, Cholesterol.
- chemical , drug effects : Antibodies, Monoclonal.
- chemical , immunology : Antibodies, Monoclonal, Proprotein Convertases, Serine Endopeptidases.
- blood : Hypercholesterolemia.
- drug therapy : Hypercholesterolemia.
- immunology : Hypercholesterolemia.
- Adolescent, Adult, Aged, Apoptosis, Double-Blind Method, Drug Administration Schedule, Drug Therapy, Combination, Drug Tolerance, Female, Follow-Up Studies, Humans, Male, Proprotein Convertase 9, Treatment Outcome, Young Adult.
Abstract
This study sought to evaluate the efficacy and safety of subcutaneous evolocumab compared with oral ezetimibe in hypercholesterolemic patients who are unable to tolerate effective statin doses.
DOI: 10.1016/j.jacc.2014.03.019
PubMed: 24694531
Affiliations:
- Australie, Espagne, France, Pays-Bas, États-Unis
- Californie, Hollande-Septentrionale, Ohio, État de New York, Île-de-France
- Amsterdam, Paris
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 003710
- to stream PubMed, to step Curation: 003596
- to stream PubMed, to step Checkpoint: 003596
- to stream Ncbi, to step Merge: 001929
- to stream Ncbi, to step Curation: 001929
- to stream Ncbi, to step Checkpoint: 001929
- to stream Main, to step Merge: 003C51
- to stream Main, to step Curation: 003C02
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab.</title><author><name sortKey="Stroes, Erik" sort="Stroes, Erik" uniqKey="Stroes E" first="Erik" last="Stroes">Erik Stroes</name><affiliation wicri:level="3"><nlm:affiliation>Department of Vascular Medicine, Academic Medical Center, Amsterdam, the Netherlands. Electronic address: e.s.stroes@amc.uva.nl.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">Pays-Bas</country><wicri:regionArea>Department of Vascular Medicine, Academic Medical Center, Amsterdam</wicri:regionArea><placeName><settlement type="city">Amsterdam</settlement><region nuts="2" type="province">Hollande-Septentrionale</region></placeName></affiliation></author><author><name sortKey="Colquhoun, David" sort="Colquhoun, David" uniqKey="Colquhoun D" first="David" last="Colquhoun">David Colquhoun</name><affiliation wicri:level="1"><nlm:affiliation>Wesley Medical Centre, Auchenflower, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Wesley Medical Centre, Auchenflower</wicri:regionArea><wicri:noRegion>Auchenflower</wicri:noRegion></affiliation></author><author><name sortKey="Sullivan, David" sort="Sullivan, David" uniqKey="Sullivan D" first="David" last="Sullivan">David Sullivan</name><affiliation wicri:level="1"><nlm:affiliation>Department of Clinical Biochemistry, Royal Prince Alfred Hospital, Camperdown, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Clinical Biochemistry, Royal Prince Alfred Hospital, Camperdown</wicri:regionArea><wicri:noRegion>Camperdown</wicri:noRegion></affiliation></author><author><name sortKey="Civeira, Fernando" sort="Civeira, Fernando" uniqKey="Civeira F" first="Fernando" last="Civeira">Fernando Civeira</name><affiliation wicri:level="1"><nlm:affiliation>Hospital Universitario Miguel Servet, Zaragoza, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Hospital Universitario Miguel Servet, Zaragoza</wicri:regionArea><wicri:noRegion>Zaragoza</wicri:noRegion></affiliation></author><author><name sortKey="Rosenson, Robert S" sort="Rosenson, Robert S" uniqKey="Rosenson R" first="Robert S" last="Rosenson">Robert S. Rosenson</name><affiliation wicri:level="2"><nlm:affiliation>Cardiometabolic Disorders Department, Icahn School of Medicine at Mount Sinai, New York, New York.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Cardiometabolic Disorders Department, Icahn School of Medicine at Mount Sinai, New York</wicri:cityArea></affiliation></author><author><name sortKey="Watts, Gerald F" sort="Watts, Gerald F" uniqKey="Watts G" first="Gerald F" last="Watts">Gerald F. Watts</name><affiliation wicri:level="1"><nlm:affiliation>Lipid Disorders Clinic, Royal Perth Hospital, School of Medicine and Pharmacology, University of Western Australia, Perth, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Lipid Disorders Clinic, Royal Perth Hospital, School of Medicine and Pharmacology, University of Western Australia, Perth</wicri:regionArea><wicri:noRegion>Perth</wicri:noRegion></affiliation></author><author><name sortKey="Bruckert, Eric" sort="Bruckert, Eric" uniqKey="Bruckert E" first="Eric" last="Bruckert">Eric Bruckert</name><affiliation wicri:level="3"><nlm:affiliation>Hopital Pitie-Salpetriere, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Hopital Pitie-Salpetriere, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Cho, Leslie" sort="Cho, Leslie" uniqKey="Cho L" first="Leslie" last="Cho">Leslie Cho</name><affiliation wicri:level="2"><nlm:affiliation>Preventive Cardiology and Rehabilitation, Cleveland Clinic, Cleveland, Ohio.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Ohio</region></placeName><wicri:cityArea>Preventive Cardiology and Rehabilitation, Cleveland Clinic, Cleveland</wicri:cityArea></affiliation></author><author><name sortKey="Dent, Ricardo" sort="Dent, Ricardo" uniqKey="Dent R" first="Ricardo" last="Dent">Ricardo Dent</name><affiliation wicri:level="2"><nlm:affiliation>Amgen, Thousand Oaks, California.</nlm:affiliation><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Amgen, Thousand Oaks</wicri:cityArea></affiliation></author><author><name sortKey="Knusel, Beat" sort="Knusel, Beat" uniqKey="Knusel B" first="Beat" last="Knusel">Beat Knusel</name><affiliation wicri:level="2"><nlm:affiliation>Amgen, Thousand Oaks, California.</nlm:affiliation><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Amgen, Thousand Oaks</wicri:cityArea></affiliation></author><author><name sortKey="Xue, Allen" sort="Xue, Allen" uniqKey="Xue A" first="Allen" last="Xue">Allen Xue</name><affiliation wicri:level="2"><nlm:affiliation>Amgen, Thousand Oaks, California.</nlm:affiliation><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Amgen, Thousand Oaks</wicri:cityArea></affiliation></author><author><name sortKey="Scott, Rob" sort="Scott, Rob" uniqKey="Scott R" first="Rob" last="Scott">Rob Scott</name><affiliation wicri:level="2"><nlm:affiliation>Amgen, Thousand Oaks, California.</nlm:affiliation><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Amgen, Thousand Oaks</wicri:cityArea></affiliation></author><author><name sortKey="Wasserman, Scott M" sort="Wasserman, Scott M" uniqKey="Wasserman S" first="Scott M" last="Wasserman">Scott M. Wasserman</name><affiliation wicri:level="2"><nlm:affiliation>Amgen, Thousand Oaks, California.</nlm:affiliation><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Amgen, Thousand Oaks</wicri:cityArea></affiliation></author><author><name sortKey="Rocco, Michael" sort="Rocco, Michael" uniqKey="Rocco M" first="Michael" last="Rocco">Michael Rocco</name><affiliation wicri:level="2"><nlm:affiliation>Cardiovascular Medicine Department, Cleveland Clinic, Cleveland, Ohio.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Ohio</region></placeName><wicri:cityArea>Cardiovascular Medicine Department, Cleveland Clinic, Cleveland</wicri:cityArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:24694531</idno><idno type="pmid">24694531</idno><idno type="doi">10.1016/j.jacc.2014.03.019</idno><idno type="wicri:Area/PubMed/Corpus">003710</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003710</idno><idno type="wicri:Area/PubMed/Curation">003596</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">003596</idno><idno type="wicri:Area/PubMed/Checkpoint">003596</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">003596</idno><idno type="wicri:Area/Ncbi/Merge">001929</idno><idno type="wicri:Area/Ncbi/Curation">001929</idno><idno type="wicri:Area/Ncbi/Checkpoint">001929</idno><idno type="wicri:Area/Main/Merge">003C51</idno><idno type="wicri:Area/Main/Curation">003C02</idno><idno type="wicri:Area/Main/Exploration">003C02</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab.</title><author><name sortKey="Stroes, Erik" sort="Stroes, Erik" uniqKey="Stroes E" first="Erik" last="Stroes">Erik Stroes</name><affiliation wicri:level="3"><nlm:affiliation>Department of Vascular Medicine, Academic Medical Center, Amsterdam, the Netherlands. Electronic address: e.s.stroes@amc.uva.nl.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">Pays-Bas</country><wicri:regionArea>Department of Vascular Medicine, Academic Medical Center, Amsterdam</wicri:regionArea><placeName><settlement type="city">Amsterdam</settlement><region nuts="2" type="province">Hollande-Septentrionale</region></placeName></affiliation></author><author><name sortKey="Colquhoun, David" sort="Colquhoun, David" uniqKey="Colquhoun D" first="David" last="Colquhoun">David Colquhoun</name><affiliation wicri:level="1"><nlm:affiliation>Wesley Medical Centre, Auchenflower, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Wesley Medical Centre, Auchenflower</wicri:regionArea><wicri:noRegion>Auchenflower</wicri:noRegion></affiliation></author><author><name sortKey="Sullivan, David" sort="Sullivan, David" uniqKey="Sullivan D" first="David" last="Sullivan">David Sullivan</name><affiliation wicri:level="1"><nlm:affiliation>Department of Clinical Biochemistry, Royal Prince Alfred Hospital, Camperdown, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Clinical Biochemistry, Royal Prince Alfred Hospital, Camperdown</wicri:regionArea><wicri:noRegion>Camperdown</wicri:noRegion></affiliation></author><author><name sortKey="Civeira, Fernando" sort="Civeira, Fernando" uniqKey="Civeira F" first="Fernando" last="Civeira">Fernando Civeira</name><affiliation wicri:level="1"><nlm:affiliation>Hospital Universitario Miguel Servet, Zaragoza, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Hospital Universitario Miguel Servet, Zaragoza</wicri:regionArea><wicri:noRegion>Zaragoza</wicri:noRegion></affiliation></author><author><name sortKey="Rosenson, Robert S" sort="Rosenson, Robert S" uniqKey="Rosenson R" first="Robert S" last="Rosenson">Robert S. Rosenson</name><affiliation wicri:level="2"><nlm:affiliation>Cardiometabolic Disorders Department, Icahn School of Medicine at Mount Sinai, New York, New York.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Cardiometabolic Disorders Department, Icahn School of Medicine at Mount Sinai, New York</wicri:cityArea></affiliation></author><author><name sortKey="Watts, Gerald F" sort="Watts, Gerald F" uniqKey="Watts G" first="Gerald F" last="Watts">Gerald F. Watts</name><affiliation wicri:level="1"><nlm:affiliation>Lipid Disorders Clinic, Royal Perth Hospital, School of Medicine and Pharmacology, University of Western Australia, Perth, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Lipid Disorders Clinic, Royal Perth Hospital, School of Medicine and Pharmacology, University of Western Australia, Perth</wicri:regionArea><wicri:noRegion>Perth</wicri:noRegion></affiliation></author><author><name sortKey="Bruckert, Eric" sort="Bruckert, Eric" uniqKey="Bruckert E" first="Eric" last="Bruckert">Eric Bruckert</name><affiliation wicri:level="3"><nlm:affiliation>Hopital Pitie-Salpetriere, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Hopital Pitie-Salpetriere, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Cho, Leslie" sort="Cho, Leslie" uniqKey="Cho L" first="Leslie" last="Cho">Leslie Cho</name><affiliation wicri:level="2"><nlm:affiliation>Preventive Cardiology and Rehabilitation, Cleveland Clinic, Cleveland, Ohio.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Ohio</region></placeName><wicri:cityArea>Preventive Cardiology and Rehabilitation, Cleveland Clinic, Cleveland</wicri:cityArea></affiliation></author><author><name sortKey="Dent, Ricardo" sort="Dent, Ricardo" uniqKey="Dent R" first="Ricardo" last="Dent">Ricardo Dent</name><affiliation wicri:level="2"><nlm:affiliation>Amgen, Thousand Oaks, California.</nlm:affiliation><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Amgen, Thousand Oaks</wicri:cityArea></affiliation></author><author><name sortKey="Knusel, Beat" sort="Knusel, Beat" uniqKey="Knusel B" first="Beat" last="Knusel">Beat Knusel</name><affiliation wicri:level="2"><nlm:affiliation>Amgen, Thousand Oaks, California.</nlm:affiliation><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Amgen, Thousand Oaks</wicri:cityArea></affiliation></author><author><name sortKey="Xue, Allen" sort="Xue, Allen" uniqKey="Xue A" first="Allen" last="Xue">Allen Xue</name><affiliation wicri:level="2"><nlm:affiliation>Amgen, Thousand Oaks, California.</nlm:affiliation><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Amgen, Thousand Oaks</wicri:cityArea></affiliation></author><author><name sortKey="Scott, Rob" sort="Scott, Rob" uniqKey="Scott R" first="Rob" last="Scott">Rob Scott</name><affiliation wicri:level="2"><nlm:affiliation>Amgen, Thousand Oaks, California.</nlm:affiliation><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Amgen, Thousand Oaks</wicri:cityArea></affiliation></author><author><name sortKey="Wasserman, Scott M" sort="Wasserman, Scott M" uniqKey="Wasserman S" first="Scott M" last="Wasserman">Scott M. Wasserman</name><affiliation wicri:level="2"><nlm:affiliation>Amgen, Thousand Oaks, California.</nlm:affiliation><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Amgen, Thousand Oaks</wicri:cityArea></affiliation></author><author><name sortKey="Rocco, Michael" sort="Rocco, Michael" uniqKey="Rocco M" first="Michael" last="Rocco">Michael Rocco</name><affiliation wicri:level="2"><nlm:affiliation>Cardiovascular Medicine Department, Cleveland Clinic, Cleveland, Ohio.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Ohio</region></placeName><wicri:cityArea>Cardiovascular Medicine Department, Cleveland Clinic, Cleveland</wicri:cityArea></affiliation></author></analytic><series><title level="j">Journal of the American College of Cardiology</title><idno type="eISSN">1558-3597</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Antibodies, Monoclonal (administration & dosage)</term><term>Antibodies, Monoclonal (blood)</term><term>Antibodies, Monoclonal (drug effects)</term><term>Antibodies, Monoclonal (immunology)</term><term>Apoptosis</term><term>Cholesterol (blood)</term><term>Double-Blind Method</term><term>Drug Administration Schedule</term><term>Drug Therapy, Combination</term><term>Drug Tolerance</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Hydroxymethylglutaryl-CoA Reductase Inhibitors (administration & dosage)</term><term>Hypercholesterolemia (blood)</term><term>Hypercholesterolemia (drug therapy)</term><term>Hypercholesterolemia (immunology)</term><term>Male</term><term>Proprotein Convertase 9</term><term>Proprotein Convertases (antagonists & inhibitors)</term><term>Proprotein Convertases (immunology)</term><term>Serine Endopeptidases (immunology)</term><term>Treatment Outcome</term><term>Young Adult</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Anticorps monoclonaux ()</term><term>Anticorps monoclonaux (administration et posologie)</term><term>Anticorps monoclonaux (immunologie)</term><term>Anticorps monoclonaux (sang)</term><term>Apoptose</term><term>Association de médicaments</term><term>Calendrier d'administration des médicaments</term><term>Cholestérol (sang)</term><term>Femelle</term><term>Humains</term><term>Hypercholestérolémie (immunologie)</term><term>Hypercholestérolémie (sang)</term><term>Hypercholestérolémie (traitement médicamenteux)</term><term>Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase (administration et posologie)</term><term>Jeune adulte</term><term>Mâle</term><term>Méthode en double aveugle</term><term>Proprotein convertases (antagonistes et inhibiteurs)</term><term>Proprotein convertases (immunologie)</term><term>Proprotéine convertase 9</term><term>Résultat thérapeutique</term><term>Serine endopeptidases (immunologie)</term><term>Sujet âgé</term><term>Tolérance aux médicaments</term><term>Études de suivi</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antibodies, Monoclonal</term><term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Proprotein Convertases</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Monoclonal</term><term>Cholesterol</term></keywords><keywords scheme="MESH" type="chemical" qualifier="drug effects" xml:lang="en"><term>Antibodies, Monoclonal</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies, Monoclonal</term><term>Proprotein Convertases</term><term>Serine Endopeptidases</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Anticorps monoclonaux</term><term>Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Proprotein convertases</term></keywords><keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Hypercholesterolemia</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Hypercholesterolemia</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Anticorps monoclonaux</term><term>Hypercholestérolémie</term><term>Proprotein convertases</term><term>Serine endopeptidases</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Hypercholesterolemia</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Anticorps monoclonaux</term><term>Cholestérol</term><term>Hypercholestérolémie</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Hypercholestérolémie</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Apoptosis</term><term>Double-Blind Method</term><term>Drug Administration Schedule</term><term>Drug Therapy, Combination</term><term>Drug Tolerance</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Male</term><term>Proprotein Convertase 9</term><term>Treatment Outcome</term><term>Young Adult</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Anticorps monoclonaux</term><term>Apoptose</term><term>Association de médicaments</term><term>Calendrier d'administration des médicaments</term><term>Femelle</term><term>Humains</term><term>Jeune adulte</term><term>Mâle</term><term>Méthode en double aveugle</term><term>Proprotéine convertase 9</term><term>Résultat thérapeutique</term><term>Sujet âgé</term><term>Tolérance aux médicaments</term><term>Études de suivi</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">This study sought to evaluate the efficacy and safety of subcutaneous evolocumab compared with oral ezetimibe in hypercholesterolemic patients who are unable to tolerate effective statin doses.</div></front></TEI><affiliations><list><country><li>Australie</li><li>Espagne</li><li>France</li><li>Pays-Bas</li><li>États-Unis</li></country><region><li>Californie</li><li>Hollande-Septentrionale</li><li>Ohio</li><li>État de New York</li><li>Île-de-France</li></region><settlement><li>Amsterdam</li><li>Paris</li></settlement></list><tree><country name="Pays-Bas"><region name="Hollande-Septentrionale"><name sortKey="Stroes, Erik" sort="Stroes, Erik" uniqKey="Stroes E" first="Erik" last="Stroes">Erik Stroes</name></region></country><country name="Australie"><noRegion><name sortKey="Colquhoun, David" sort="Colquhoun, David" uniqKey="Colquhoun D" first="David" last="Colquhoun">David Colquhoun</name></noRegion><name sortKey="Sullivan, David" sort="Sullivan, David" uniqKey="Sullivan D" first="David" last="Sullivan">David Sullivan</name><name sortKey="Watts, Gerald F" sort="Watts, Gerald F" uniqKey="Watts G" first="Gerald F" last="Watts">Gerald F. Watts</name></country><country name="Espagne"><noRegion><name sortKey="Civeira, Fernando" sort="Civeira, Fernando" uniqKey="Civeira F" first="Fernando" last="Civeira">Fernando Civeira</name></noRegion></country><country name="États-Unis"><region name="État de New York"><name sortKey="Rosenson, Robert S" sort="Rosenson, Robert S" uniqKey="Rosenson R" first="Robert S" last="Rosenson">Robert S. Rosenson</name></region><name sortKey="Cho, Leslie" sort="Cho, Leslie" uniqKey="Cho L" first="Leslie" last="Cho">Leslie Cho</name><name sortKey="Dent, Ricardo" sort="Dent, Ricardo" uniqKey="Dent R" first="Ricardo" last="Dent">Ricardo Dent</name><name sortKey="Knusel, Beat" sort="Knusel, Beat" uniqKey="Knusel B" first="Beat" last="Knusel">Beat Knusel</name><name sortKey="Rocco, Michael" sort="Rocco, Michael" uniqKey="Rocco M" first="Michael" last="Rocco">Michael Rocco</name><name sortKey="Scott, Rob" sort="Scott, Rob" uniqKey="Scott R" first="Rob" last="Scott">Rob Scott</name><name sortKey="Wasserman, Scott M" sort="Wasserman, Scott M" uniqKey="Wasserman S" first="Scott M" last="Wasserman">Scott M. Wasserman</name><name sortKey="Xue, Allen" sort="Xue, Allen" uniqKey="Xue A" first="Allen" last="Xue">Allen Xue</name></country><country name="France"><region name="Île-de-France"><name sortKey="Bruckert, Eric" sort="Bruckert, Eric" uniqKey="Bruckert E" first="Eric" last="Bruckert">Eric Bruckert</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003C02 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003C02 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:24694531
|texte= Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:24694531" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |